PMID- 24375541
OWN - NLM
STAT- MEDLINE
DCOM- 20140513
LR  - 20231120
IS  - 2157-6564 (Print)
IS  - 2157-6580 (Electronic)
IS  - 2157-6564 (Linking)
VI  - 3
IP  - 3
DP  - 2014 Mar
TI  - Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T 
      lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
PG  - 356-64
LID - 10.5966/sctm.2013-0135 [doi]
AB  - Targeting cancer stem cells (CSCs) with immunotherapy may be an effective means 
      to prevent recurrences in glioblastoma multiforme (GBM). It is well established 
      that CD133 is expressed in the population of GBM tumor cells representing CSCs. 
      This raises a possibility that CD133 could serve as a potential target for 
      cytotoxic T cells (CTLs) to target glioblastoma cancer stem cells. Two potential 
      human leukocyte antigen (HLA)-A*0201-restricted CD133 epitopes, ILSAFSVYV 
      (CD133-405) and YLQWIEFSI (CD133-753), showed strong binding to HLA-A*0201 
      molecules. In vitro immunogenicity studies generated peptide-specific CD8(+) CTLs 
      from normal donors. Autologous monocyte-derived dendritic cells pulsed with the 
      CD133-405 or CD133-753 peptides generated CTLs that efficiently recognized the 
      CD133 epitopes presented in T2 HLA-A*0201 cells and specifically lysed CD133+ 
      HLA-A*0201(+) GBM CSCs. These studies demonstrated natural processing and 
      subsequent presentation of these epitopes in GBM CSCs and the ability of CTLs to 
      kill CSCs bearing the antigen. Immunization studies in mice using the mouse 
      homolog CD133 epitopes demonstrated immunogenicity in the absence of autoimmune 
      damage. The results presented in this study support the use of CD133-specific 
      epitope vaccines to target CSCs in glioblastoma and other cancers.
FAU - Ji, Jianfei
AU  - Ji J
AD  - Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, 
      USA; Torrey Pines Institute for Molecular Studies, San Diego, California, USA; 
      ImmunoCellular Therapeutics, Ltd., Calabasas, Calfornia, USA.
FAU - Judkowski, Valeria A
AU  - Judkowski VA
FAU - Liu, Gentao
AU  - Liu G
FAU - Wang, Hongqiang
AU  - Wang H
FAU - Bunying, Alcinette
AU  - Bunying A
FAU - Li, Zhenhua
AU  - Li Z
FAU - Xu, Minlin
AU  - Xu M
FAU - Bender, James
AU  - Bender J
FAU - Pinilla, Clemencia
AU  - Pinilla C
FAU - Yu, John S
AU  - Yu JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131227
PL  - England
TA  - Stem Cells Transl Med
JT  - Stem cells translational medicine
JID - 101578022
RN  - 0 (AC133 Antigen)
RN  - 0 (Antigens, CD)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Glycoproteins)
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Oligopeptides)
RN  - 0 (PROM1 protein, human)
RN  - 0 (Peptides)
RN  - 0 (Prom1 protein, mouse)
SB  - IM
MH  - AC133 Antigen
MH  - Animals
MH  - Antigens, CD/genetics/*immunology
MH  - Cell- and Tissue-Based Therapy
MH  - Central Nervous System Neoplasms/genetics/immunology/pathology/*therapy
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/cytology/drug effects/immunology
MH  - Epitopes, T-Lymphocyte/genetics/*immunology
MH  - Gene Expression/immunology
MH  - Glioblastoma/genetics/immunology/pathology/*therapy
MH  - Glycoproteins/genetics/*immunology
MH  - HLA-A2 Antigen/genetics/*immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Mice
MH  - Neoplastic Stem Cells/drug effects/*immunology/pathology
MH  - Oligopeptides/chemical synthesis/immunology/pharmacology
MH  - Peptides/genetics/*immunology
MH  - Protein Binding
MH  - Secondary Prevention
MH  - T-Lymphocytes, Cytotoxic/cytology/drug effects/*immunology
PMC - PMC3952931
OTO - NOTNLM
OT  - CD133
OT  - Cancer stem cell
OT  - Cytotoxic T cell
OT  - Dendritic cell
OT  - Immunotherapy
EDAT- 2014/01/01 06:00
MHDA- 2014/05/14 06:00
PMCR- 2015/03/01
CRDT- 2013/12/31 06:00
PHST- 2013/12/31 06:00 [entrez]
PHST- 2014/01/01 06:00 [pubmed]
PHST- 2014/05/14 06:00 [medline]
PHST- 2015/03/01 00:00 [pmc-release]
AID - sctm.2013-0135 [pii]
AID - 130135 [pii]
AID - 10.5966/sctm.2013-0135 [doi]
PST - ppublish
SO  - Stem Cells Transl Med. 2014 Mar;3(3):356-64. doi: 10.5966/sctm.2013-0135. Epub 
      2013 Dec 27.